March 31st 2025
Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
CRU Eye Symposium
March 28-30, 2025
Register Now!
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(COPE Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (CME Track)
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (COPE Track)
View More
Collaborative Care Symposium
May 30-31, 2025
Register Now!
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability
View More
EP. 3: EyeCon 2022: High-impact content in a small-scale setting
October 6th 2022The setting for this year's Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide the opportunity for clinical interaction between faculty and attendees along with the practicality of information.
Read More
At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."
Watch
EP. 2: EyeCon 2022: Location, location, location and bring the family
September 28th 2022The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.
Read More
EP. 1: EyeCon 2022: Nothing is better than in-person conferences
September 21st 2022Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.
Read More
Cornea research pioneer honored with Champalimaud Vision Award
September 16th 2022Claes H. Dohlman, MD, PhD, widely considered the father of modern cornea science, is a recipient of the 2022 António Champalimaud Vision Award. The award, considered the “Nobel Prize of Vision," comes with a $1 million prize .
Read More
Presbyopia-correcting IOL receives high marks
August 26th 2022The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.
Read More
Elkin: Talking about the importance of pediatric eye health and safety
August 10th 2022Zachary Elkin, MD, MPH, of NYU Langone Eye Center, advises how ophthalmologists and parents should be aware of precautions that should be taken with sports involving small balls and urges the use of protective eyewear.
Watch
Oyster Point Pharma announces expanded patient access to varenicline solution
July 28th 2022Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray and provided an update on the commercial performance of the spray in the United States. According to the company, its expanded patient access programs include more eligible patients with dry eye disease.
Read More
FDA approves the AcuFocus IC-8 small aperture IOL for cataract surgery
July 25th 2022Results from the U.S. pivotal trial showed Apthera IOL subjects achieved statistically superior uncorrected intermediate and near vision, and equivalent distance vision and contrast sensitivity compared to control subjects.
Read More